| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41443-018-0019-5 |
| P698 | PubMed publication ID | 29795527 |
| P50 | author | Ekrem Akdeniz | Q88797236 |
| P2093 | author name string | Mustafa Suat Bolat | |
| Onder Cinar | |||
| Ramazan Aşcı | |||
| P2860 | cites work | Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action | Q26783529 |
| Effect of tadalafil 5mg daily treatment on the ejaculatory times, lower urinary tract symptoms and erectile function in patients with erectile dysfunction | Q33692658 | ||
| Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection | Q34021698 | ||
| Ejaculatory disorders: epidemiology and current approaches to definition, classification and subtyping | Q36132063 | ||
| Long term evolution of endothelial function during kidney transplantation. | Q36172106 | ||
| Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil | Q37466573 | ||
| Diabetes-induced erectile dysfunction: epidemiology, pathophysiology and management | Q37750010 | ||
| Endothelins & erectile dysfunction | Q37824029 | ||
| PDE5 inhibitors: targeting erectile dysfunction in diabetics | Q37933766 | ||
| Erectile function recovery in men treated with phosphodiesterase type 5 inhibitor administration after bilateral nerve-sparing radical prostatectomy: a systematic review of placebo-controlled randomized trials with trial sequential analysis | Q38634621 | ||
| First-generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and meta-analysis. | Q38956366 | ||
| Treatment satisfaction of men and partners following switch from on-demand phosphodiesterase type 5 inhibitor therapy to tadalafil 5 mg once daily | Q41536614 | ||
| Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels | Q45050058 | ||
| Corpora cavernosa ultrastructure in vascular erectile dysfunction | Q48923903 | ||
| Post-traumatic stress disorder, coping strategies and type 2 diabetes: psychometric assessment after L'Aquila earthquake. | Q51076225 | ||
| Phosphodiesterase 5 inhibition ameliorates angiotensin II-dependent hypertension and renal vascular dysfunction. | Q51217905 | ||
| Effects of 12 weeks of tadalafil treatment on ejaculatory and orgasmic dysfunction and sexual satisfaction in patients with mild to severe erectile dysfunction: integrated analysis of 17 placebo-controlled studies. | Q53116980 | ||
| Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. | Q53254266 | ||
| Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. | Q54355911 | ||
| Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo | Q74561887 | ||
| Let's make NO mistake! | Q81922034 | ||
| Determinants of erectile dysfunction in type 2 diabetes | Q82860997 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 102-107 | |
| P577 | publication date | 2018-05-25 | |
| P1433 | published in | International Journal of Impotence Research | Q15749221 |
| P1476 | title | Low dose daily versus on-demand high dose tadalafil in diabetic patients with erectile and ejaculatory dysfunction | |
| P478 | volume | 30 |
| Q95261659 | Development of nanotechnology in andrology | cites work | P2860 |
Search more.